公开(公告)号：US20230366894A1

公开(公告)日：2023-11-16

申请号：US18028235

申请日：2021-09-30

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Johann Karl ,  Peter Kastner ,  Roberto Latini ,  Serge Masson ,  Jennifer Marie Theresia Anna Meessen ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  André Ziegler

IPC: G01N33/74

CPC classification number: G01N33/74 ,  G01N2333/58 ,  G01N2440/38 ,  G01N2800/326

Abstract: The present invention relates to a method for diagnosing atrial fibrillation in a subject, said method comprising the steps of a) determining the amount of total NT-proBNP in sample from the subject, b) determining the amount of unglycosylated NT-proBNP in a sample from the subject, c) calculating a score of the amounts determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing atrial fibrillation in a subject.

公开(公告)号：US20230062697A1

公开(公告)日：2023-03-02

申请号：US17821951

申请日：2022-08-24

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Dirk Block ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler

IPC: G01N33/68 ,  G01N33/74

Abstract: The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.

公开(公告)号：US20190353666A1

公开(公告)日：2019-11-21

申请号：US16217612

申请日：2018-12-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Herbert Andres ,  Dirk Block ,  Johann Karl ,  Peter Kastner ,  Ursula-Henrike Wienhues-Thelen ,  Roberto Latini ,  Serge Masson ,  Andre Ziegler ,  Edelgard Kaiser ,  Stefan Palme ,  Markus Thomas ,  Simona Barlera

IPC: G01N33/68

Abstract: The present disclosure relates to a method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. The present disclosure also contemplates a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Further envisaged are devices adapted to carry out the method of the present disclosure.

公开(公告)号：US20170227552A1

公开(公告)日：2017-08-10

申请号：US15581587

申请日：2017-04-28

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Roberto Latini ,  Serge Masson ,  Dirk Block ,  Christian Zaugg ,  Thomas Dieterle ,  Edelgard Kaiser ,  Johann Karl ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen

IPC: G01N33/68

Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.